Trevi Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 20, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 20, 2024
TRVI$14.33+11.9%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31,2023 | December 31,2022 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $32,397 | $12,589 |
| Marketable securities | 50,574 | 107,921 |
| Prepaid expenses | 3,621 | 795 |
| Other current assets | 955 | 1,311 |
| Total current assets | 87,547 | 122,616 |
| Operating lease right-of-use assets | 1,137 | 24 |
| Other non-current assets | 297 | 205 |
| Property, equipment and leasehold improvements, net | 216 | 170 |
| Finance lease right-of-use assets | 206 | — |
| Total assets | $89,403 | $123,015 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $1,809 | $2,857 |
| Accrued expenses | 3,709 | 3,518 |
| Operating lease liabilities | 184 | 25 |
| Finance lease liabilities | 122 | — |
| Term loan | — | 7,000 |
| Total current liabilities | 5,824 | 13,400 |
| Operating lease liabilities | 1,001 | 2 |
| Finance lease liabilities | 31 | — |
| Term loan | — | 2,151 |
| Other non-current liabilities | — | 3 |
| Total liabilities | 6,856 | 15,556 |
| Commitments and contingencies (Note 13) | ||
| Stockholders’ equity: | ||
| Preferred stock: $0.001 par value; 5,000,000 shares authorized at December 31, 2023 and December 31, 2022; no shares issued or outstanding at December 31, 2023 and December 31, 2022. | — | — |
| Common stock: $0.001 par value; 200,000,000 shares authorized at December 31, 2023 and December 31, 2022; and 68,283,699 and 59,943,430 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively. | 68 | 60 |
| Additional paid-in capital | 321,642 | 317,590 |
| Accumulated other comprehensive loss | (29) | (122) |
| Accumulated deficit | (239,134) | (210,069) |
| Total stockholders’ equity | 82,547 | 107,459 |
| Total liabilities and stockholders’ equity | $89,403 | $123,015 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.